New drug combo aims to fight returning brain tumors

NCT ID NCT07431216

Not yet recruiting Disease control Sponsor: Starlight Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called STAR-001 combined with the blood pressure medication spironolactone in about 68 people whose glioblastoma has returned after initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants receive STAR-001 by IV twice per cycle and take spironolactone pills before each infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STAR-001 (LP-184) combined with spironolactone
What this could lead to: If it works, this could offer a new treatment option for people with glioblastoma that has returned after initial therapy, potentially shrinking tumors and extending life.
What could go wrong: This is an early-phase trial with only 68 participants, so results may not apply to all patients. The combination may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 4 glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM) HISTOPATHOLOGY CONFIRMED SUPRATENTORIAL GBM AT FIRST RECURRENCE IDHM GRADE 4 ASTROCYTOMA IDHWT GBM

More trials for these conditions

Other studies related to the condition(s) this trial covers.